News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Arena Pharmaceuticals, Inc.'s Weight-loss Medication Lorcaserin Comparable to Orlistat or Sibutramine, Florida Hospital in Winter Park Study
July 15, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
MedPage Today -- Combined with lifestyle modifications, the investigational weight-loss medication lorcaserin reduced weight without major safety problems, a multicenter, phase III trial showed.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase III
MORE ON THIS TOPIC
Allergies
Regeneron’s Antibodies Block Cat and Birch Allergies With ‘Robust Activity’
September 9, 2025
·
2 min read
·
Tristan Manalac
Drug Development
If Data Is the New Oil, AI Is the Refinery
September 8, 2025
·
5 min read
·
Lori Ellis
Neuroscience
Alkermes One Ups Takeda in Narcolepsy, Clearing Cognitive Impairments in Mid-Stage Trial
September 8, 2025
·
2 min read
·
Dan Samorodnitsky
Neuroscience
Rapport Jumps 180% on ‘Best Case’ Mid-Stage Data for Epilepsy Pill
September 8, 2025
·
2 min read
·
Heather McKenzie